ストックスクリーナーアプリを入手
24.12
1.24%
0.295
アフターアワーズ：
24.37
0.25
+1.04%
Palvella Therapeutics Inc (PVLA) 最新ニュース
Palvella Therapeutics Secures New Patent for QTORIN™ Rapamycin - MyChesCo
Palvella Therapeutics Receives US Patent for Qtorin Topical Gel Candidate - MarketScreener
Palvella Therapeutics Granted Sixth U.S. Patent Covering - GlobeNewswire
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1-20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors - The Manila Times
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of - Bluefield Daily Telegraph
Palvella's Game-Changing QTORIN Patent Locks in 15+ Years of Market Protection for Rare Disease Treatment - Stock Titan
Palvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN Rapamycin - MSN
Cantor Fitzgerald Weighs in on PVLA FY2026 Earnings - Defense World
Palvella Therapeutics Holds Annual Stockholders Meeting - TipRanks
Palvella Therapeutics (NASDAQ:PVLA) Receives $46.29 Consensus Price Target from Analysts - Defense World
Palvella Therapeutics receives FDA grant for rare disease trial By Investing.com - Investing.com South Africa
Palvella Therapeutics Says Top-Line Data From SELVA Expected In Q1 2026 - marketscreener.com
Palvella Therapeutics receives FDA grant for rare disease trial - Investing.com
Palvella Therapeutics Receives Initial Proceeds from FDA - GlobeNewswire
Citadel Advisors LLC Makes New Investment in Palvella Therapeutics (NASDAQ:PVLA) - Defense World
Palvella Therapeutics Names Ashley Kline Chief Commercial Officer - MSN
Palvella Therapeutics Advances in Rare Skin Disease Therapies - TipRanks
A great week for institutional investors who own 26% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) - simplywall.st
Palvella Therapeutics Strengthens Executive Leadership Team - GlobeNewswire
Palvella Therapeutics hires Ashley Kline as Chief Commercial Officer - Investing.com
Palvella Therapeutics hires Ashley Kline as Chief Commercial Officer By Investing.com - Investing.com India
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer - The Manila Times
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease ... - Eagle-Tribune
Palvella Taps Rare Disease Star Who Led $500M Oxervate Launch for Upcoming Genetic Disease Treatment - Stock Titan
Brokers Set Expectations for PVLA FY2025 Earnings - Defense World
Palvella Therapeutics Reports Q1 2025 Financials and Clinical Progress - MSN
Canaccord Genuity Group Has Lowered Expectations for Palvella Therapeutics (NASDAQ:PVLA) Stock Price - Defense World
Palvella Therapeutics to Announce Q1 2025 Financial Results and Host Investor Call - MSN
Mineralys Therapeutics Announces Q1 2025 Financial Results and Achievements - MyChesCo
Analysts Set Palvella Therapeutics (NASDAQ:PVLA) Price Target at $44.43 - Defense World
Palvella Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Palvella Therapeutics: Q1 Earnings Snapshot - CT Insider
Earnings call transcript: Palvella Therapeutics reports Q1 2025 loss, stock dips - Investing.com Nigeria
Palvella Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Palvella Therapeutics Reports Strong Q1 Financial Results - TipRanks
PALVELLA THERAPEUTICS Earnings Results: $PVLA Reports Quarterly Earnings - Nasdaq
PALVELLA THERAPEUTICS, INC. SEC 10-Q Report - TradingView
Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Palvella's Breakthrough Skin Disease Treatment Hits Major Milestone as Phase 3 Trial Surpasses Target - Stock Titan
Palvella Therapeutics (PVLA) Projected to Post Quarterly Earnings on Thursday - Defense World
Palvella Therapeutics Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Palvella Therapeutics Rings the Opening Bell - Nasdaq
Palvella Therapeutics to Ring Nasdaq Opening Bell - MyChesCo
Palvella Therapeutics to Host First Quarter 2025 Financial - GlobeNewswire
0.68%
0.50%
大文字化:
|
ボリューム (24 時間):